FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2231-2239 May 22, 2008 Number 21 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Purchase this article Editorial by Miller, J. W. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

SUMMARY

Early-onset, severe retinal dystrophy caused by mutations in the gene encoding retinal pigment epithelium–specific 65-kD protein (RPE65) is associated with poor vision at birth and complete loss of vision in early adulthood. We administered to three young adult patients subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA) under the control of a human RPE65 promoter. There were no serious adverse events. There was no clinically significant change in visual acuity or in peripheral visual fields on Goldmann perimetry in any of the three patients. We detected no change in retinal responses on electroretinography. One patient had significant improvement in visual function on microperimetry and on dark-adapted perimetry. This patient also showed improvement in a subjective test of visual mobility. These findings provide support for further clinical studies of this experimental approach in other patients with mutant RPE65. (ClinicalTrials.gov number, NCT00643747 [ClinicalTrials.gov] .)

Source Information

From the Institute of Ophthalmology, University College London (J.W.B.B., A.J.S., S.S. Barker, S.R., R.H., K.B., A.V., G.E.H., A.S., S.S. Bhattacharya, F.W.F., G.S.R., A.T.M., R.R.A.); Moorfields Eye Hospital (J.W.B.B., A.V., G.E.H., A.T.M.); the National Institute of Health Research Biomedical Research Centre for Ophthalmology, University College London and Moorfields Eye Hospital (J.W.B.B., G.S.R., A.T.M., R.R.A.); the Department of Civil and Environmental Engineering, University College London (N.T.); and the Institute of Child Health, University College London (A.J.T., R.R.A.) — all in London; Michigan State University, East Lansing (S.P.-J.); and Targeted Genetics Corporation, Seattle (B.J.C.).

Drs. Bainbridge and Smith contributed equally to this article.

This article (10.1056/NEJMoa0802268) was published at www.nejm.org on April 27, 2008.

Address reprint requests to Dr. Ali at the Institute of Ophthalmology, University College London, Bath St., London EC1V 9EL, United Kingdom, or at r.ali{at}ucl.ac.uk.

Full Text of this Article

This article has been cited by other articles:

• (2008). Gene Therapy for Congenital Retinal Degeneration. JWatch Neurology 2008: 1-1 [Full Text]  
• Miller, J. W. (2008). Preliminary Results of Gene Therapy for Retinal Degeneration. NEJM 358: 2282-2284 [Full Text]